Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer

Summary

This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.

Eligibility

Inclusion Criteria:

* Pathologically or cytologically confirmed lung cancer.
* Scheduled to receive first-line platinum-based chemotherapy.
* Aged 18 to 75 years.
* Karnofsky Performance Status (KPS) score ≥ 60.
* Expected survival ≥ 3 months.
* Voluntarily signed written informed consent.

Exclusion Criteria:

* Known allergy to any component of the acupoint plaster.
* Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women.
* Cognitive impairment or psychiatric disorder that prevents completion of study assessments.
* Participation in another interventional clinical trial within 30 days prior to enrollment.

Conditions3

Interventions1

Browse More Trials